A Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors Who Failed to Imatinib and Sunitinib.

Trial Profile

A Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors Who Failed to Imatinib and Sunitinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jan 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top